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1. INTRODUCTION 
 
1.1. Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium 
characterised primarily by left ventricular myocardial hypertrophy, predominantly 
involving the interventricular septum [reviewed in detail in (1-4)]. The cavity of the left 
ventricle is typically narrow. According to current literature data the disease is more 
frequent, then it was previously thought as its prevalence was shown to be 1/500-1000 (5). 
Clinically the patients may be asymptomatic, but the development of symptoms in form of 
dyspnoea, chest pain, palpitation or syncope is more typical. Arrhythmias are frequent and 
the risk of sudden cardiac death is also increased. 
 
1.2. Molecular genetics of hypertrophic cardiomyopathy 
Genetic studies have shown that in most cases HCM is a hereditary disease with a typical 
autosomal dominant inheritance, variable penetrance and expression. Using molecular 
genetic methods specific alterations in genes encoding for mainly sarcomere proteins were 
found to cause the disease [reviewed in detail in (6,7)]. The most important affected genes 
implicated in the disease include the beta myosin heavy chain- (MYH7) (8), the alpha 
tropomyosin- (TPM1) (9), the troponin T- (TNNT2) (9), the myosin binding protein C- 
(MYBPC3) (10,11), the troponin I- (TNNI3) (12), the essential- (MYL3) and the regulatory 
myosin light chain- (MYL2) (13), the alpha-cardiac actin- (ACTC1) (14) and the titin (TTN) 
genes (15) (Table 1). Based on the above, HCM can be considered as the disease of the 
sarcomere (9). Other genes, affecting genes encoding for the sarcomere Z-disk [muscle 
LIM protein- (CSRP3) (16); telethonin- (TCAP) (17); myozenin 2- (MYOZ2) (18); 
vinculin/metavinculin- (VCL) (19); alfa actinin-2- (ACTN2) (20); cypher-LIM binding 
domain 3 (ZASP/LBD3) genes (21)], and encoding for Ca++-handling proteins 
[junctophyllin-2- (JPH2) (22,23); phospholamban (PLN) genes (24)] has been also 
implicated causing HCM in selected cases (Table 2). Mutations affecting sarcomere genes 
are present in 40-60% of HCM patients. In 5-10% of the cases mutations affect genes 
which may lead to HCM phenocopies (i.e. Fabry disease, Danon disease, transthyretin 
amyloidozis, etc.) (25). In the remaining 20-25% of the cases the cause of HCM is still 
unknown (2). 
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Although HCM is a genetically heterogeneous disease, the most commonly affected 
sarcomere gene that can cause HCM is the myosin binding protein C gene (MYBPC3). 
According to literature data on screening different patient populations with HCM the 
prevalence of mutations affecting the MYBPC3 gene is 15-25% (26-41). Since the 
identification of the first MYBPC3 gene mutation nearly 600 other mutations have been 
identified in the gene. Our team published the first MYBPC3 gene mutation in a Hungarian 
patient in 2001 (42). 
 
Gene Symbol Locus Prevalence (%) 
beta myosin heavy chain MYH7 14q12 15-25 
myosin binding protein C MYBPC3 11p11.2 15-25 
troponin T TNNT2 1q32 <5 
troponin I TNNI3 19q13.4 <5 
troponin C TNNC1 3p21-p14 <1 
alpha-tropomyosin TPM1 15q22 <5 
alpha cardiac actin ACTC1 15q14 <1 
essential myosin light chain MYL3 3p21.31 <1 
regulatory myosin light chain MYL2 12q24.21 <2 
titin TTN 2q31 <1 
AMP activated protein kinase, γ2 
regulatory subunit 
PRKAG2 7q34-q36 <1 
 
Table 1. Affected sarcomere genes and their prevalence in hypertrophic cardiomyopathy. 
 
Gene Symbol Locus Prevalence (%) 
muscle LIM protein CSRP3 11p15 <1 
telethonin TCAP 17q12 <1 
myozenin 2 MYOZ2 4q26 <1 
vinculin/metavinculin VCL 10q22.1 <1 
alfa actinin-2 ACTN2 1q42 <1 
cypher-LIM binding domain 3 ZASP/LBD3 10q22.3 1-5 
junctophyllin-2 JPH2 20q12 <1 
phospholamban PLN 6q22.1 <1 
 
Table 2. Affected Z-disk and Ca++-handling genes and their prevalence in hypertrophic cardiomyopathy. 
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1.3. Structure and function of the myosin binding protein C (cMyBP-C) 
The structure and sequence of the human MYBPC3 gene have been determined in 1997 
(43). It encompasses more than 21 kbp and is composed of 34 coding exons. The gene 
encodes cardiac myosin binding protein C (cMyBP-C) which is a multi-modular structural 
protein component of the sarcomere [reviewed in detail in (44-47)]. The cMyBP-C is a 
polypeptide, which belongs to the intracellular immunoglobulin superfamily. The protein 
consists multiple domains, and can be found in the myofibrillum of every striated muscle 
tissue of the body, binding to the thick filament of the sarcomere, except the Purkinje cells 
of the heart. The protein itself is located in the ’C’ („crossbridge”) zone of the ‘A’ band of 
the sarcomere, 43 nm from each other, as a form of 7-9 stripes (Figure 1). The cMyBP-C 
protein is made up of eight immunoglobulin I (IgI) and three fibronectin III (FnIII) 
domains (C0-C10) (Figure 2). 
 
 
 
Figure 1. The localization of cardiac myosin protein binding C in the sarcomere (Source: Bonne G et al. 
Circ Res 1998; 83: 580-93.) 
 
There are three known isoforms of the MyBP-C protein in the human body: the fast 
skeletal muscle, the slow skeletal muscle (originally that was mentioned as MyBP-C-X) 
and the cardiac isoform. The different isoforms of the protein are encoded by separate 
genes; the fast skeletal type is encoded by MYBPC2 on chromosome 19, and the slow 
skeletal type is encoded by MYBPC1 on chromosome 12. The cardiac type is encoded by 
the MYBPC3, located on chromosome 11. All isoforms are fibre type specific, the cardiac 
type can be found only in the heart. The cardiac isoform differs in 3 basic aspects from the 
skeletal muscle types. First, the cardiac type has an extra immunoglobulin I motif on the 
N-terminal (C0), the function of which is still unclear. Second, there is a proline-rich 
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region in the middle of the C5 IgI domain in the cardiac type. Third, there are two more 
phosphorylation sites in the linker region that consist of nearly 100 amino acids and links 
to each other the C1 and the C2 domains (Figure 2). Although the precise role of the 
cMyBP-C protein in the sarcomere structure and in the process of contraction-relaxation is 
still unclear, it appears that it has both structural and regulatory function.  
 
Figure 2. Schematic representation of the structure of the cardiac myosin protein binding C. The eleven 
domains of the cMyBP-C protein (C0-C10) including the eight immunoglobulin I (IgI) domains (green) and 
the three fibronectin III (FnIII) domains (blue) are shown. The phosphorylation, myosin- and titin binding 
sites are indicated. 
 
1.4. Mutations affecting the MYBPC3 gene in hypertrophic cardiomyopathy 
Using linage analysis, the presence of an HCM locus was mapped in 1993 to chromosome 
11 (11p11.2) (48). Further research identified the MYBPC3 gene as the causative gene of 
the locus in 1995 when mutations were found in different families with HCM in the 
MYBPC3 gene (10,11). In one of the families a partial duplication of the gene was 
identified that contained 18 base pairs, which extended the mutant protein by 6 amino 
acids. In three other families a “splice site” mutation was described which caused an early 
termination of the protein and resulted in a truncated protein.  
Ever since numerous mutations have been identified that can affect the gene: the 
professional version of the Human Gene Mutation Database (HGMD, www.hgmd.cf.ac.uk) 
lists 614 MYBPC3 gene mutations. Early studies screening for mutations in the MYBPC3 
gene found a 13-26% prevalence of MYBPC3 gene mutations in patients with HCM. 
Erdmann et al. who investigated 110 patients found a 13.6% prevalence in a German HCM 
cohort (49), while Van Driest et al., screening 389 patients, and Richard et al., who 
analysed 197 patients, reported an occurrence of 18% (37) and 26%, respectively (35). 
Approximately two-thirds of the MYBPC3 mutations result in a truncated protein. This 
phenomenon can be attributed to either so-called „splice-site” mutations, or nucleotide 
insertions or deletions, which all can cause a shift in the reading frame. This will lead to 
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incorporation of nonsense sequences which will usually end by an early stop codon 
activation. Besides, several missense mutations were identified which result in the change 
of only one amino acid (44,47,50). 
 
1.5. The p.Gln1233Ter mutation of the MYBPC3 gene 
Some of the MYBPC3 mutations have a debated consequence. Such a mutation is the 
p.Gln1233Ter MYBPC3 mutation of the gene which is caused by a C-T transition in exon 
33 of the MYBPC3 gene (c.3697C>T). The mutation leads to the initiation of a premature 
stop codon instead of glutamine at codon 1233 (p.Gln1233Ter). This presumably causes 
the loss of the terminal 48 amino acids of the myosin binding protein C which contains 
binding sites for myosin and titin. 
The p.Gln1233Ter mutation of MYBPC3 has been reported by three groups in the 
literature. In a report, originating from Germany, the mutation has been described in two 
families with Turkish origin, in which three mutation carriers were identified (49). 
Haplotype analysis suggested a founder effect in the apparently unrelated families. 
However, affected-to-affected transmission of the mutation was not possible to prove 
owing to the small family size and availability of samples. Another report came from 
Australia, where the p.Gln1233Ter mutation was identified in one patient in a “compound” 
form in association with another MYBPC3 mutation (p.Gln1233Ter/p.Arg326Gln) (51). 
Again, transmission of the mutation from affected-to-affected was not demonstrated. In a 
third report, originating from the USA, the p.Gln1233Ter mutation has been also identified 
in a HCM proband, but also in normal controls with an incidence of 2%, and, therefore, it 
was regarded more a polymorphism (37). Therefore, the importance of the mutation has 
been questioned based on two arguments; 1) no affected-to-affected transmission has ever 
been demonstrated; and 2) presence in apparently normal controls in some populations. Of 
note, with regard to the latter observation, the mutation was neither detected in 50 normal 
controls in the German group (49), nor in 300 negative controls in the Australian group 
(51). 
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2. AIMS 
Previous to our work, no information were available with regard to the occurrence, 
prevalence, or distribution of MYBPC3 gene mutations in Hungarian patients with 
hypertrophic cardiomyopathy. Similarly, no data existed on possible specific genotype-
phenotype correlations, penetrance rates or specific expression of the disease in a 
Hungarian HCM patient cohort. 
Therefore, in my PhD work I aimed to: 
1. Identify mutations affecting the myosin binding protein C gene (MYBPC3) in Hungarian 
patients with hypertrophic cardiomyopathy; 
2. Establish the prevalence rate of MYBPC3 mutations in Hungarian HCM patient 
population; 
3. Conduct clinical and genetic screening of family members of patients with MYBPC3 
gene mutations; 
4. Analyze genotype-phenotype correlations of MYBPC3 mutations identified in Hungarian 
HCM patients; 
5. Characterize specific MYBPC3 mutations identified in the Hungarian HCM cohort. 
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3. PATIENTS AND METHODS 
3.1. Patients  
3.1.1. Hungarian patients with hypertrophic cardiomyopathy screened for mutations 
in the MYBPC3 gene 
We analyzed forty-five unrelated patients with hypertrophic cardiomyopathy. In all cases 
collection of case history data, physical examination, overview of available clinical 
documentation, 12-lead ECG and transthoracic echocardiography were carried out. In 
selected cases patients were hospitalized for detailed in-hospital cardiology assessment 
(24-hour Holter monitoring, stress test, semi-supine bicycle stress echocardiography, 
cardiac MRI, coronarography, haemodynamic study). In all cases the diagnosis of HCM 
was based on internationally accepted diagnostic criteria (2-4).  
The demographic characteristics, the main data on the course of the disease, as well as on 
the main echocardiographic characteristics of the patients are shown in Table 3. The 
average maximum left ventricular wall thickness were 226 mm, in 40 cases typical 
asymmetric septal hypertrophy, in 3 cases apical HCM were identified. In 15 cases 
significant resting left ventricular outflow tract obstruction (greater than 30 mmHg) were 
present. In the 45 analyzed probands during the average 87 years (median: 6 years) 
follow-up period 9 deaths occurred, 8 of them were sudden cardiac death. In 6 patients 
ICD implantation, in 2 cases DDD pacemaker implantation, in 3 cases percutaneous 
transluminal septal myocardial ablation (PTSMA), in 2 cases surgical myomectomy were 
carried out. In one case HCM transformed into dilated phase, and the patient underwent 
heart transplantation.  
 
3.1.2. Family members of patients with hypertrophic cardiomyopathy carrying 
MYBPC3 gene mutations for clinical and genetic investigations 
Family members of 5 index patients were investigated in whom 5 different, specific 
MYBPC3 gene mutations were identified by our previous investigations [c.3697C>T 
(p.Gln1233Ter); c.821+1G>A; c.2864_2865delCT (p.Pro955ArgfsTer95); 
c.1776_1777delGT (p.Ser593ProfsTer11); c.3407_3409delACT (p.Tyr1136del)]. Family 
members of the index patient carrying the c.431_432delGT (p.Gly144AlafsTer8) mutation 
were not available for family screening. 
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total number of patients, n (%) 45 (100%) 
male, n (%) 27 (60%) 
mean age (at diagnosis, year) 38±15 
familiarity proven, n (%) 18 (40%) 
death, n (%) 9 (20%) 
cause of the death, n (%)  
 sudden cardiac death 8 (89%) 
 other (suicide) 1 (11%) 
atrial fibrillation, n (%) 11 (24%) 
intervention  
 ICD implantation, n (%) 6 (13%) 
 Pacemaker implantation, n (%) 2 (4%) 
 PTSMA, n (%) 3 (7%) 
 PCI, n (%) 2 (4%) 
 Myomectomy, n (%) 2 (4%) 
 HTX, n (%) 1 (2%) 
Echocardiography data  
 
Maximal left ventricular wall 
thickness (mm) 
22±6 
 hypertrophy localization, n ASH: 40, apical: 3, other: 2 
 left atrium diameter, mm 45±11 
 LVEDD, mm 45±11 
 LVESD, mm 28±13 
 EF, % 61±12 
 LVOT gradient at rest, mmHg 26±29 
 
LVOT gradient at rest >30 
mmHg, n (%) 
15 (30%) 
 
Table 3. The main demographic, clinical and echocardiographic parameters of the patient population with 
HCM screened for MYBPC3 gene mutations. ICD: implantable cardioverter defibrillator, PTSMA: 
percutaneous transluminal septal myocardial ablation, PCI: percutaneous coronary intervention, HTX: 
heart transplantation, LV: left ventricle, ASH: asymmetric hypertrophy, LVEDD: left ventricular end-
diastolic diameter, LVESD: left ventricular end-systolic diameter, EF: ejection fraction, LVOT: left 
ventricular outflow tract. 
 
Altogether, 62 family members (30 male, 32 female, age: 40±18 years) were investigated 
in the 5 families. In all cases collection of case history data, physical examination, 
overview of available clinical documentation, 12-lead ECG and transthoracic 
echocardiography were carried out. In selected cases patients were hospitalized for detailed 
in-hospital cardiology assessment (24-hour Holter monitoring, stress test, semi-supine 
bicycle stress echocardiography, cardiac MRI, coronarography, haemodynamic study). In 
all cases diagnosis of HCM were based on internationally accepted diagnostic criteria (2-
4), in case of the family members the McKenna criteria were considered (52).  
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3.2 Methods 
3.2.1. Genetic analysis 
In accordance with legal regulations all investigated patients and family members gave 
written informed consent to molecular genetic analyses. DNA isolation was carried out 
using standard methodology from peripheral blood samples. The complete coding 
sequence and exon-intron junctions of the MYBPC3 gene (1-35 exons) was amplified by 
polymerase chain reaction (PCR) from the sample DNAs (Mastercycler Gradient, 
Eppendorf AG, Hamburg, Germany) with specific primer pairs described in the literature 
(10). In general, the samples were amplified in 25 l PCR reaction using 100 ng DNA 
template with optimized PCR protocols. The PCR products were analysed by ’single strand 
conformation polymorphism’ (SSCP) or ’denaturing high performance liquid 
chromatography” (DHPLC) chromatography mutation analysis methods (Figure 3), which 
were based on the different temperature-dependent separation of the DNA sample carrying 
a different nucleotide (variant). The DHPLC analysis was carried out on a Helix (Varian 
Inc, Palo Alto, USA) DHPLC equipment. The optimum melting temperature of all specific 
PCR fragments were defined by using the DHPLC Melt Programme 
(http://insertion.stanford.edu/melt.html). After PCR the denatured samples were renatured 
by slow cooling (1C/min). The elution curves of the samples were analysed by the 
programme of the equipment (Star Reviewer, version 2.0). Every abnormal chromatogram 
was sequenced using the ABI PRISM 310 automated sequencer. 
 
 
Figure 3. Denaturing high performance liquid chromatography (DHPLC) analysis of a normal (green) and 
mutant (red) PCR fragment. The method is based on the different temperature-dependent separation of the 
DNA sample carrying a different nucleotide (variant). After PCR the denatured samples are renatured by 
slow cooling than eluted from a DNA-binding column at an optimum melting temperature of the specific PCR 
fragments. If a nucleotide change (i.e. variant) is present in the sample, the elution curves are different. 
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3.2.2. Bioinformatics 
Assessing the nucleotide variants and determining the mutations the Ensemble database of 
the European Molecular Biology Laboratory- European Bioinformatics Institute was used 
(www.ensemble.org). For reporting variants, LRG_386 was used as a stable genomic 
reference framework for describing sequence variants for this gene (transcript: 
LRG_386t1, protein: LRG_386p1). The dbSNP database (Single Nuleotide Polymorphism 
Database ) of the National Centre for Biotechnology Information was used as a variation 
reference (http://www.ncbi.nlm.nih.gov/SNP/), while the HGMD database (Human Gene 
Mutation Database) of the at the Institute of Medical Genetics in Cardiff was used as a 
mutation reference. 
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4. RESULTS 
4.1. Identification of MYBPC3 mutations in Hungarian patients with hypertrophic 
cardiomyopathy 
4.1.1. Mutation data 
In the 45 analyzed patients with HCM we identified 6 (13%) different causative MYBPC3 
mutations (Table 4 and Figures 4-5). One of the mutations was a nonsense (stop codon) 
mutation in exon 33 of the gene (c.3697C>T, p.Gln1233Ter, Figure 4, Panel A and B). 
Another mutation was a splice site mutation at the junction of exon and intron 7 
(c.821+1G>A, Figure 4, Panel C and D). In other three cases three 2 base-pair 
microdeletions, affecting exons 27, 18 and 4 were found, which resulted in ‘frame-shift’ 
[exon 27: c.2864_2865delCT (p.Pro955ArgfsTer95, Figure 4, Panel E and F); exon 18: 
c.1776_1777delGT (p.Ser593ProfsTer11, Figure 5, Panel A and B); exon 4: 
c.431_432delGT, (p.Gly144AlafsTer8, Figure 5, Panel E and F)]. The sixth identified 
mutation was a 3 base-pair microdeletion affecting exon 31, which did not cause ‘frame 
shift’ but led to the deletion of a single amino acid (c.3407_3409delACT, p.Tyr1136del, 
Figure 5, Panel C and D). Each mutation was present in heterozygous form. Three of the 
mutations were previously reported in the literature (p.Gln1233ter, c.821+1G>A, 
c.2864_2865delCT) while the other three were novel mutations. Besides the causative 
mutations we identified several intronic polymorphisms, that do not affect the coding 
sequence of the gene, furthermore, several ’silent’ mutations that do not change the 
sequence of the amino acids (intron 2: g.1505G>C; intron 21: g.13170A>G; intron 21: 
g.13090A>T; intron 33: g.20756C>T). 
patient 
affected 
exon 
affected 
codon 
nucleotide change amino acid change reported 
HGMD 
No. 
dbSNP No. reference 
H 16.0 33 1233 c.3697C>T p.Gln1233ter yes CM014069 rs397516037 37, 49, 51 
H 11.0 
exon/ 
intron7 
- c.821+1G>A - yes CS982276 rs397516073 37, 49, 58 
H 65.0 27 955 c.2864_2865delCT p.Pro955ArgfsTer95 yes CD982813 rs397515990 49, 58 
H 92.0 18 592-593 c.1776_1777delGT p.Ser593ProfsTer11 no - rs730880713  
H 76.0 31 1136 c.3407_3409delACT p.Tyr1136del no - rs730880674  
H 55.0 4 144 c.431_432delGT p.Gly144AlafsTer8 no - rs397516047  
 
Table 4. Identified MYBPC3 mutations in the Hungarian HCM patient cohort. Del: deletion, fs: frame-shift, 
HGMD: Human Gene Mutation Database, dbSNP: Single Nucleotide Polymorphism Database. 
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Figure 4. Electropherograms of MYBPC3 gene mutations identified in Hungarian HCM patients. Panel A: a 
C to T transition in exon 33 in patient H 16.0 (c.3697C>T) resulting in nonsense (stop codon) mutation 
p.Gln1233Ter. Panel C: a G to A transition at the junction of exon and intron 7 in patient H 11.0 
(c.821+1G>A) resulting in a splice site mutation. Panel E: a CT 2-bp deletion in exon 27 in patient H65.0 
(c.2864_2865delCT) resulting in mutation p.Pro955ArgfsTer95. The mutation sites are highlighted in red 
brackets. Panel B, D and F illustrate the corresponding normal sequences. 
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Figure 5. Electropherograms of MYBPC3 gene mutations identified in Hungarian HCM patients. Panel A: a 
GT 2-bp microdeletion in exon 18 in patient H 92.0 (c.1776_1777delGT), leading to mutation 
p.Ser593ProfsTer11; Panel C: an ACT 3-bp microdeletion in exon 31 in patient H 76.0 
(c.3407_3409delACT), leading to the deletion of a single amino acid, p.Tyr1136del; Panel E: a GT 2-bp 
microdeletion in exon 4 in patient H 55.0 (c.431_432delGT), leading to mutation p.Gly144AlafsTer8. The 
mutation sites are highlighted in red brackets. Panel B, D and F illustrate the corresponding normal 
sequences. 
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4.1.2. Clinical data 
The main clinical parameters of the patients with MYBPC3 mutations are shown in Table 
5. 
 
patient 
ID 
mutation gender 
age (at diag-
nosis, year) 
LVmax 
(mm) 
hypertrophy 
localisation 
follow up 
H 16.0 p.Gln1233Ter female 43 32 ASH 
death due to stroke at 
the age of 49 years 
H 11.0 c.821+1G>A male 21 26 ASH 
transformation into 
dilated phase, AF 
H 65.0 p.Pro955ArgfsTer95 female 54 25 ASH 
alive, no significant 
progression 
H 92.0 p.Ser593ProfsTer11 male 43 16 ASH 
SCD at the age of 59 
years 
H 76.0 p.Tyr1136del male 54 26 ASH 
SCD at the age of 56 
years 
H 55.0 p.Gly144AlafsTer8 female 40 24 ASH 
alive, no significant 
progression 
 
Table 5. The main clinical parameters of the index patients carrying MYBPC3 gene mutations. ASH: 
asymmetric septal hypertrophy; SCD: sudden cardiac death, LVmax: maximum left ventricular wall 
thickness. 
 
4.1.2.1. c.3697C>T, p.Gln1233Ter mutation 
We identified the p.Gln1233Ter mutation of the MYBPC3 gene (Figure 4, Panel A and B) 
in a female proband (H 16.0) who was diagnosed with HCM at age 43 after presenting 
with signs of diastolic heart failure. Echocardiography revealed marked septum 
hypertrophy (maximum left ventricular wall thickness: 32 mm) without left ventricular 
outflow tract obstruction. During follow up thinning of the septum with the decrease of the 
left ventricular ejection fraction and increase of mitral regurgitation was noted. She died 
suddenly at age 49, due to cerebral embolism from a left ventricular thrombus, according 
to autopsy data. The case history of the patient - who was the first patient in Hungary with 
a MYBPC3 mutation identified - has already been described in detail in a previous 
publication (42). 
4.1.2.2. c.821+1G>A mutation 
The second causative MYBPC3 mutation was identified in a 54-year-old male patient (H 
11.0), who was first hospitalized due to chest pain at the age of 21. HCM was diagnosed 
with moderate septal hypertrophy (maximal left ventricle wall thickness: 26 mm) and with 
the phenomenon of ’systolic anterior motion’ (SAM) on echocardiography. Past medical 
history of the patient revealed that that he was also deaf-mute (19). During last follow-up, 
at the age of 53, septal thickness of 22 mm, enlarged left atrium (61 mm), enlarged left 
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ventricular dimensions (LV end-diastolic diameter: 59 mm, LV end-systolic diameter: 36 
mm), reduced left ventricular ejection fraction (48%) were measured with the 
disappearance of SAM phenomenon and the development of atrial fibrillation. The clinical 
characteristics of the case was published previously as Csanady’s cardiomyopathy (53) and 
was included into the London Dysmorphology Database. 
Genetic analysis revealed a G-A transition at the border of exon 7 and intron 7 of the 
MYBPC3 gene that affects the splice donor site of exon 7 (c.821+1G>A, Figure 4, Panel C 
and D). The mutation also affects the recognition site of restriction endonuclease Eco72I, 
so the mutation was verified by endonuclease digestion (Figure 6). 
 
 
 
 
 
 
 
 
Figure 6. Eco72I restriction fragment analysis of the c.821+1G>A mutation. Due to the mutation, a 
restriction site is lost for the restriction enzyme Eco72I, and after digestion additional, undigested fragments 
are seen in the mutant samples. Lane 1: wild type, Eco72I digested; lane 2: wild type, non-digested; lane 3: 
mutant, Eco72I digested; lane 4: mutant, non-digested. 
 
4.1.2.3. c.2864_2865delCT, p.Pro955ArgfsTer95 mutation 
The third MYBPC3 gene mutation was identified in a 68-year-old female patient (H 65.0) 
who was first hospitalized at the age of 54 due to chest pain. On echocardiography, non-
obstructive HCM was diagnosed that caused moderate left ventricle hypertrophy 
(maximum LV wall thickness: 25 mm). Risk stratification indicated low risk for sudden 
cardiac death. Using combined beta-blocker and calcium channel blocker therapy the 
patient is in a stable clinical status, no progression was seen at the last follow up. In her 
family one of her brothers also suffers from HCM.  
In exon 25 of the MYBPC3 gene a 2 base-pair CT microdeletion was identified by 
molecular genetic testing (c.2864_2865delCT, p.Pro955ArgfsTer95, Figure 4, Panel E and 
1 2 3 4 
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F). The mutation is a frame-shift mutation that causes a p.Pro955Arg amino acid change 
after the normal alanine amino acid in position 954, which is followed by the incorporation 
of 95 aberrant amino acids before the translation stops at this point due to a hidden stop 
codon (Figure 7).  
4.1.2.4. c.1776_1777delGT, p.Ser593ProfsTer11 mutation 
The fourth MYBCP3 gene mutation was identified in a 43-year-old male patient (H 92.0) 
whose disease manifested with symptoms of chest pain occurring at rest, dyspnea and pre-
syncope. On echocardiography mild septal hypertrophy (maximal left ventricular wall 
thickness: 16 mm) and a non-significant left ventricular outflow tract gradient was 
detected. Over the years his disease progressed into dilated phase with increasing left 
ventricular parameters and decreasing left ventricular ejection fraction. At his last follow-
up echocardiography parameters showed septal thickness of 15 mm, left atrial diameter of 
55 mm, left ventricular end-systolic diameter of 44 mm, left ventricular ejection fraction of 
31%. The development of atrial fibrillation was also noted. His death occurred at the age of 
59 suddenly.  
Molecular genetic analysis detected a 2 base-pair (GT) microdeletion in exon 18 of the 
MYBPC3 gene (c.1776_1777delGT, Figure 5, Panel A and B). The mutation leads to a 
frame shift that causes a p.Ser593Pro amino acid change after the normal lysine amino acid 
in position 592 followed by incorporation of 11 aberrant amino acids before the translation 
stops due to a hidden TGA stop codon (p.Ser593ProfsTer11, Figure 7).  
4.1.2.5. c.3407_3409delACT, p.Tyr1136del mutation 
The p.Tyr1136del mutation of the MYBPC3 gene was detected in a male patient (H 76.0) 
who was diagnosed with HCM at age of 54 years after an accidental discovery of a heart 
murmur. Echocardiography showed significant asymmetric septal hypertrophy (maximal 
left ventricular wall thickness: 26 mm) with a non-significant LV outflow tract gradient 
(18 mmHg). Risk stratification indicated a low risk profile, however, during his follow-up 
loss of consciousness occurred 2 times under exercise. His death occurred at the age of 56 
suddenly. Mutation analysis indicated a 3 base-pair (ACT) microdeletion in exon 31 of the 
MYBPC3 gene (c.3407_3409delACT, Figure 5, Panel C and D). Interestingly, the 
mutation leads to an in-frame deletion of only one amino acid, tyrosine, in position of 1136 
(p.Tyr1136del, Figure 7). 
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4.1.2.6. c.431_432delGT, p.Gly144AlafsTer8 mutation 
The p.Gly144AlafsTer8 mutation of the MYBPC3 gene was detected in a female patient (H 
55.0) with HCM, who was diagnosed with HCM at age of 40 years, when she was 
hospitalized because of chest pain and dyspnea. Echocardiography revealed a maximum 
left ventricular wall thickness of 24 mm with the appearance of non-obstructive HCM. 
During her follow up left ventricular outflow tract obstruction (43 mmHg) and subsequent 
enlargement of the left atrium was detected (53 mm).  
Her genetic analysis confirmed a GT microdeletion (c.431_432delGT, Figure 5, Panel E 
and F) in the exon 4 of the MYBPC3 gene. The mutation leads to a p.Gly144Ala amino 
acid change after the normal asparagine amino acid in position 143 followed by 
incorporation of 8 aberrant amino acids before the translation stops due to a hidden stop 
codon (p.Gly144AlafsTer8, Figure 7). 
 
Figure 7. Presumed consequences of the MYBPC3 gene mutations identified in Hungarian patients with 
HCM. The eleven domains of the cMyBP-C protein (C0-C10), including the eight immunoglobulin I (IgI) 
domains (green) and three fibronectin III (FnIII) domains (blue) are shown. The phosphorylation, myosin- 
and titin binding sites are indicated. The presumed truncated parts of the mutant protein are shown in red. 
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4.2. Clinical and genetic investigations of families of patients with hypertrophic 
cardiomyopathy carrying MYBPC3 gene mutations 
4.2.1. Mutation data 
Mutation carrier status was verified in 30 of the 62 (48%) investigated family members 
(p.Gln1233Ter: 3/7, c.821+1G>A: 7/20, p.Pro955ArgfsTer95: 15/30, p.Ser593ProfsTer11: 
2/2, p.Tyr1136del: 3/3; Table 6). The mutation occurred in heterozygous form in every 
family member. 
 
family mutation 
screened family 
member (n) 
mutation 
carrier (n) 
clinically  
affected (n) 
H 16 p.Gln1233Ter 7 3 1 
H 11 c.821+1G>A 20 7 5 
H 65 p.Pro955ArgfsTer95 30 15 2 
H 92 p.Ser593ProfsTer11 2 2 1 
H 76 p.Tyr1136del 3 3 1 
All  62 30 10 
 
Table 6. Main data of the genetic and clinical screening in the MYBPC3 gene mutation carrier families. 
 
4.2.2. Clinical data 
Clinical diagnosis of HCM could be verified in 10 of the 30 (33%) mutation carrier family 
members, including the index patients. The main clinical parameters of the mutation carrier 
index patients and the affected family members are included in Table 7. HCM was verified 
in 5 of the 7 mutation carrier family members in family H 11, and in 2 of the 15 mutation 
carrier family members in family H 65. In the remaining three families (H 16, H 76, H 92) 
there was no clinically manifest family member with HCM, except for the index cases.  
In family H 65, the proband’s brother (H 65.3) was verified with HCM whose disease was 
diagnosed at age of 76. His disease was characterised by asymmetric septal hypertrophy, 
the maximum left ventricle wall thickness was 17 mm, without outflow tract gradient. 
During risk stratification low risk was verified. He deceased at the age of 83 which was 
unrelated to HCM (gastric cancer). Family details regarding family H 11 is described under 
4.3.  
In clinically affected mutation carriers the diagnosis of HCM was established at the age of 
27 the earliest, and at the age of 76 the latest. Nine patients were diagnosed with HCM 
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above the age of 40, and 6 patients above the age of 50 years. In case of the clinically 
affected mutation carriers the average age at the diagnosis was significantly higher than in 
case of the clinically not affected family members (51±13 vs. 38±17 years, p=0.028). 
During the 10±8 years (median: 8 years) follow-up period 6 patients died out of the 10 
clinically affected mutation carriers (60%) at the average age of 58±10 years, 9±4 years 
after 
 
patient 
ID 
mutation gender 
age (at 
diagnosis, 
year) 
LVmax 
(mm) 
hypertrophy 
localisation 
follow up 
H 16.0 p.Gln1233Ter female 43 32 ASH 
death due to stroke at the 
age of 50 
H 11.0 c.821+1G>A male 21 26 ASH 
transformation into 
dilated phase, AF 
H 11.1 c.821+1G>A male 63 26 ASH SCD at the age of 72 
H 11.15 c.821+1G>A male 42 26 ASH SCD at the age of 51 
H 11.22 c.821+1G>A male 52 13 ASH 
alive, no significant 
progression 
H 11.3 c.821+1G>A male 59 15 ASH 
AF, endocarditis, AVR, 
MVR 
H 65.0 p.Pro955ArgfsTer95 female 54 25 ASH 
alive, no significant 
progression 
H 65.3 p.Pro955ArgfsTer95 male 76 17 ASH 
death at the age of 83, 
unrelated to HCM  
H 92.0 p.Ser593ProfsTer11 male 43 16 ASH SCD at the age of 59 
H 76.0 p.Tyr1136del male 54 26 ASH SCD at the age of 56 
 
Table 7. The main clinical parameters of the clinically manifest probands and family members with HCM 
who carries the MYBPC3 gene mutation. ASH: asymmetric septal hypertrophy; SCD: sudden cardiac death, 
LVmax: maximum left ventricular wall thickness, AVR: aortic valve replacement; MVR: mitral valve 
replacement. 
 
the diagnosis. In 4 cases the cause of the death was sudden cardiac death, in one case it was 
stroke and in the last case the death was unrelated to HCM (gastric cancer). In case of the 
20 clinically unaffected mutation carriers no death occurred. 
 
4.3. Observation of extreme phenotypic variability in a HCM family carrying the 
MYBPC3 c.821+1G>A gene mutation  
In family H 11 five patients were diagnosed with manifest HCM (Figure 8). The index 
patient’s case history was already detailed under 4.1.2.2. The index patient’s father (H 
11.1) was diagnosed with the disease at the age of 63 (interventricular septal thickness: 26 
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mm), and died suddenly at the age of 72. In case of the younger brother of the index patient 
(H 11.15) hypertrophic cardiomyopathy has been developed over the time, in the form of 
typical ASH. A manifest cochlear hearing loss was also associated, diagnosed at the age of 
48 (the cochlear loss of hearing was unequivocal left sided, on the right it was moderate). 
During cardiology follow-up, the echocardiography parameters or symptomatic status of 
the patient showed no progression, nevertheless, at the age of 51 he died suddenly while 
sleeping. In case of the older brother of the index patient (H 11.22) we also observed the 
development of  
 
 
Figure 8. Part of pedigree of the MYBPC3 c.821+1G>A mutation carrier HCM family. Squares and circles 
denote males or females, respectively; filled symbols represent clinically affected family members. Arrow 
points to the index patient. Deceased individuals are slashed. Mutation carriers are labelled with a plus (+) 
sign, non-carriers with a minus (–) sign. 
 
hypertrophic cardiomyopathy in the form of asymmetric septal hypertrophy. Beside the 
current medical therapy the cardiac status of the patient is stable. The younger brother of 
the index patient (H 11.3) was also proved to have manifest hypertrophic cardiomyopathy. 
In his case the typical non-obstructive asymmetric septal hypertrophy was diagnosed at the 
age of 59 in a cardiology screening. One year later he was hospitalised several times due to 
cardiac decompensation and paroxysmal atrial fibrillation. Shortly thereafter bacterial 
endocarditis developed which necessitated aortic and mitral valves replacement. Besides 
family members manifesting HCM we observed a symptom-free mutation carriers (H 11.4, 
H 11.28, H 11.16), who are completely free of signs or symptoms of the disease, and has a 
normal ECG and echocardiography parameters. Thus, we observed an extremely variable 
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phenotype with regard to the MYBPC3 c.821+1G>A gene mutation, including symptom-
free mutation carrier, sudden cardiac death, progression into dilated phase and 
complications of infective endocarditis. 
 
4.4. Analysis of the p.Gln1233Ter mutation of the MYBPC3 gene in three carrier 
families  
Further studies identified the MYBPC3 p.Gln1233Ter mutation in three, apparently not-
related index patients, including patient H 16.0, whose case history was given in 4.1.2.1. In 
the second, male index patient (H 214.0, see family tree, Figure 9 and Table 8) the 
diagnosis of HCM was done at age 33, based on cardiology assessment initiated because of 
frequent occurrence of syncope. Echocardiography showed moderate septum hypertrophy 
(21 mm), with systolic anterior movement of the anterior mitral valve leaflet and a left 
ventricular peak outflow tract gradient of 55 mmHg which rose to 88 mmHg on the 
Valsalva manoeuvre. Invasive measurement also verified significant resting (45-58 mmHg) 
and provocable (158-165 mmHg) obstruction. Based on his clinical condition and findings 
myectomy and later PM implantation was performed. In the third, female index patient (H 
109.0, see family tree, Figure 9 and Table 8) HCM was diagnosed at age 62, based on 
echocardiography which was initiated because heart enlargement was detected on a routine 
chest X-ray film in the otherwise symptom-free patient. Echocardiography revealed 
moderate left ventricular hypertrophy, most pronounced at the interventricular septum (23 
mm), and with left ventricular outflow tract peak resting gradient of 35 mmHg. 
patient sex clinical status 
age (at diagnosis or 
last FU, yrs) 
LVmax 
(mm) 
follow up 
H 16.0 F affected 43 32 died of stroke at age 49 
H 16.1 F not-affected 34 10 alive, without major symptoms 
H 16.3 M not affected 18 8 alive, without major symptoms 
H 214.0 M affected 33 21 myectomy, PM implantation 
H 214.1 F affected 14 33 alive, without major symptoms 
H 214.2 M not affected 37 12 alive, without major symptoms 
H 109.0 F affected 62 23 alive, without major symptoms 
H 109.2 F affected 38 18 alive, without major symptoms 
 
Table 8. Major clinical parameters of the MYBPC3 p.Gln1233Ter mutation carrier family members. FU: 
follow up, LVmax: maximal left ventricular thickness. 
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Figure 9. Pedigrees of the MYBPC3 p.Gln1233Ter mutation carrier HCM families. Squares and circles 
denote males or females, respectively; filled symbols represent clinically affected family members. Arrow 
points to the index patients. Deceased individuals are slashed. Mutation carriers are labelled with a plus (+) 
sign, non-carriers with a minus (–) sign. 
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Clinical and genetic family screening of the three families indicated 8 mutation carriers 
(including the index patients) among the 19 family members screened in the three families 
(Figure 9 and Table 8). Of the 8 mutation carriers the clinical diagnosis of HCM was 
established in 5 family members (Table 8). Importantly, affected-to-affected transmission 
of the mutation was seen in two of the three families. Haplotype analysis did not prove a 
founder effect. The mutation was not identified in 149 apparently normal healthy controls 
(neither in 218 patients with dilated cardiomyopathy, nor in 97 other patients with 
hypertrophic cardiomyopathy; 928 chromosomes in total).  
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5. DISCUSSION 
5.1. Identification of MYBPC3 mutations in Hungarian patients with hypertrophic 
cardiomyopathy 
According to literature data, the most frequently affected gene causing HCM is the 
MYBPC3 gene. Initial studies reported a prevalence rate of 13-26% for the occurrence of 
MYBPC3 gene mutations in HCM patient cohorts. Erdmann et al. reported a 13.6% 
prevalence (28) in the 110 patients she investigated, while Van Driest et al. found in 18% 
(37) of 389 patients, and Richard et al. found in 26% (35) of the 197 patients they assessed. 
Later studies on disease gene distribution in HCM confirmed a 10-35% occurrence rate of 
MYBPC3 gene mutations in HCM (Table 9). The most recent figure for MYBPC3 gene 
involvement is coming from studies which used next generation sequencing technology for 
genotyping. Lopés et al. studied 223 unrelated patients with HCM, in whom they analyzed 
coding, intronic and regulatory regions of 41 cardiovascular genes, by means of massive 
parallel resequencing. In the cohort they identified 46 MYBPC3 gene variants, which gives 
a prevalence rate of 21% (54).  
 
Cohort  
Patients, 
No. 
Screened 
genes, No. 
Sarcomeric gene 
mutation (%) 
MYBPC3 gene 
mutation (%) 
Sequencing 
methodology 
Richard et al. (35) 197 9 63 26.4 SSCP+DS 
Morner et al. (33) 46 8 28 20 SSCP /DHPLC 
Erdmann et al. (28) 108 6 33.3 18.5 SSCP+DS or RFLP 
Van Driest et al. (37-39) 389 8 37.7 18.2 DHPLC+DS 
Olivotto et al. (34) 203 8 62 34 DHPLC+DS+RFLP 
Garcia-Castro et al. (29) 120 5 26.7 16 DS 
Andersen et al. (26) 90 11 36 10 SSCP+DS 
Laredo et al. (31)+ 
Rodriguez-Garcia et al. (36) 
130 2 23 15 SSCP+DS+RFLP 
Millat et al. (32) 192 4 48 25 DHPLC+DS 
Waldmuller et al. (40) 236 2 41 24 DS 
Brito et al. (27) 77 5 53 35 DS 
Gruner et al. (30) 471 8 35 14.9 DS 
Zou et al. (41) 200 8 51 18 DS 
 
Table 9. Studies on investigating gene mutations frequencies in different HCM cohorts. DHPLC, denaturing 
high performance liquid chromatography DS, direct sequencing; RFLP, restriction fragment length 
polymorphism; SSCP, single strand conformation polymorphism. 
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In the 45 analyzed Hungarian patients with HCM we identified 6 different causative 
MYBPC3 mutations establishing a 13% prevalence rate of the MYBPC3 gene mutations in 
the Hungarian HCM patient population. This occurrence rate is very well in agreement 
with literature data. Considering our previous data, where we found that the mutation rate 
of the beta myosin heavy chain gene (MYH7) in the Hungarian patient population was 5% 
(55), and in 100 Hungarian patients with HCM we found no troponin I (TNNI3) (56) or 
troponin T (TNNT2) mutations (57), the MYBPC3 gene seems to be the most commonly 
affected gene in the Hungarian patient population with HCM.  
Two of the mutations identified by us were point mutations (p.Gln1233Ter, c.821+1G>A), 
the others were 2-3 base pairs microdeletions (c.2864_2865delCT, c.1776_1777delGT, 
c.431_432delGT, c.3407_3409delACT). Three of the microdeletions produced “frame-
shift” mutations that resulted in the incorporation of aberrant amino acids and then the 
activation of a stop codon, leading to truncated proteins at the C terminal end.  
The c.821+1G>A point mutation that affects the junction site of exon/intron 7 is a classical 
splice-site mutation which also results in the activation of a hidden stop codon and the 
formation of a truncated protein, similarly to the p.Gln1233Ter point mutation which is a 
stop codon mutation. Due to the stop codon activation the translation of the protein stops, 
and exons located distally from the stop codon will be not transcribed and the C terminal 
part of the protein will be truncated. Except the p.Tyr1136del mutation all the mutations’ 
probable effect is the deletion of the distal part of the protein, which part is responsible for 
the myosin and titin binding function of the protein. Direct evidence for the above could 
have been provided from the analysis of mRNA extracted from the heart muscle, but as no 
native myocardium was available it was not possible to directly prove it. 
The fourth microdeletion is an “in-frame” deletion which causes the deletion of only one 
amino acid (p.Tyr1136del). At positions 1135-1136 of the cMyBP-C protein, which is part 
of the C9 motif, two Tyr locates. Both are evolutionally conserved amino acids that 
highlights a functionally important role [the Tyr1135 is identical in the human, in the 
mouse, in the chicken and in the fugu (Japanese pufferfish, Takifugu rubripesis); the 
Tyr1136 is identical in the human and in the mouse, in the chicken Phe, in the fugu Val can 
be found in identical position].  
Three of the mutations we identified have already been published in the literature 
(p.Gln1233Ter, c.821+1G>A, p.Pro955ArgfsTer95). The p.Gln1233Ter mutation had been 
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already reported by three research teams. Erdmann et al. detected the mutation in two 
families with Turkish origin, where three mutation carrier were identified (49). The disease 
of the mutation carriers started between at the age of 25-41, their maximum left ventricular 
wall thickness were 17-20 mm. In four additional family members who were clinically 
relevant but genetically not tested, sudden cardiac death occurred. By the haplotype 
analysis of the mutant allele it was possible to detect that the apparently unrelated families 
inherited a common “founder” haplotype (so-called “founder” mutation). Van Driest et al. 
detected the p.Gln1233Ter mutation in the patient population of the Mayo Clinic, 
interestingly, they detected the variant in 2% of the 400 control reference alleles and on 
this basis they regarded the variant as a rare polymorphism (37). According to the 2005 
publication of Ingles et al. the p.Gln1233Ter/Arg326Gln “compound” mutation of the 
MYBPC3 gene was detected in only one member of a family, in whom the maximum left 
ventricular wall thickness was 28 mm (51). The c.821+1G>A mutation was also reported 
by three research group (discussed under 5.3). The p.Pro955ArgfsTer95 mutation is also 
known in the literature. It was first mentioned in the article of Niimura et al. published in 
1998 (58), where it was proved in a four-generation family. Eighteen mutation carriers 
were described, from whom 8 family members were clinically affected. In that family 3 
deaths occurred due to HCM. In the paper of the Mayo Clinic this mutation was also 
described (37). The three other mutations out of the six mutations we detected previously 
were not published (p.Ser593ProfsTer11, p.Gly144AlafsTer8, p.Tyr1136del). Although the 
p.Ser593ProfsTer11 mutation was not previously published, there is a report in the 
literature on the p.Val592fs mutation which is almost identical with the one we identified. 
The latter was described in a couple of Japanese families and was proven that it is a 
“founder” mutation (59). Interestingly, 23% of the mutation carrier 30 manifest patients 
with HCM transformed into end-stage dilated form. In case of our p.Ser593ProfsTer11 
mutation carrier patient we also observed the progression into dilated phase, the 
development of atrial fibrillation and sudden cardiac death. 
 
5.2. Clinical and genetic investigations of families of patients with hypertrophic 
cardiomyopathy carrying MYBPC3 gene mutations 
Analysing families of index patients with MYBPC3 gene mutations we found that 30 of the 
62 (48%) screened family members were mutation carriers, which ratio is in agreement 
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with autosomal dominant nature of inheritance. Among the 30 mutation carrier patients, we 
observed the development of HCM in 10 patients, including the index patients (33%).  
With regard to the clinical presentation of the MYBPC3 gene mutations earlier publications 
reported about non-significant left ventricular hypertrophy, mild symptoms and good 
prognosis. Charron et al. in their 1998 publication described the investigation of 76 
patients with MYBPC3 gene mutation, whom they found that the prognosis of patients with 
MYBPC3 gene mutations was significantly better (no death under the age of 40), the 
symptoms of the disease occurred significantly later and the thickness of left ventricle was 
significantly less compared to patients with HCM carrying beta myosin gene mutation 
(60). Investigating 48 patients carrying the MYBPC3 gene mutation Richard et al. 
perceived 55% benign, 35% intermediate and 10% malignant appearance forms in terms of 
cardiac complications including HCM related death due to sudden cardiac death, heart 
failure or stroke, heart transplantation and resuscitated cardiac death (35). Subsequent 
publications have found no difference between patients carrying MYBPC3 mutations and 
patients carrying other HCM mutations. Erdmann et al. investigating 29 patients carrying 
MYBPC3 mutations and 11 patients carrying beta myosin heavy chain mutations found no 
significant difference between the appearance of the disease and its main clinical 
parameters (extent of left ventricular hypertrophy, myectomy, necessity of septal ablation) 
(49). Investigating 63 patients carrying the MYBPC3 mutations and 61 patients carrying 
beta myosin heavy or light chain mutations Van Driest et al. similarly found no substantive 
difference with regard to the clinical appearance (age at time of diagnosis, extent of left 
ventricle hypertrophy, necessity of myectomy or ICD implantation) (37). 
In a recent meta-analysis, looking at genotype-phenotype correlations, Lopés et al. pooled 
patients from eighteen publications (corresponding to a total of 2459 patients). They 
reported that the presence of any sarcomere gene mutation was associated with a 
significantly younger age at presentation (38.4 vs. 46.0 years), a family history of HCM 
(50.6% vs. 23.1%), family history of SCD (27.0% vs. 14.9%). and greater maximal LV 
wall thickness (21.0 vs. 19.3 mm). There were no differences when the two most 
frequently affected genes, MYBPC3 and MYH7, were compared (61). 
In our patient population we observed a malignant appearance in the 10 clinically affected 
patients carrying MYBPC3 mutations, 6 of them deceased at average age of 58 years. Five 
of the 6 above-mentioned deaths were probably HCM-related, including 4 cases of sudden 
cardiac death, and one case of stroke. In two additional patients, serious, HCM-related 
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progressive disease were observed with a transition into dilated phase and development of 
endocarditis. The 20 clinically not manifest family members carrying the mutation showed 
no signs or symptoms of the disease, seemed to be asymptomatic and no death occurred. 
The latter observation also suggest that not the mutation carrier status itself, but the clinical 
manifestation and characteristics of HCM determine prognosis.  
Interestingly, in patients carrying MYBPC3 gene mutation, HCM was possible to be 
diagnosed above 50 years which means prolonged clinical manifestation or long 
asymptomatic stage. That delayed clinical manifestation of the MYBPC3 gene mutations is 
well documented in the literature. Niimura et al. investigating 212 mutation carrier 
members of 16 families found that it was possible to verify HCM in 58% of mutation 
carriers under the age of 50, and the penetrance of the mutation also did not reach 100% 
above the age of 60 (58). It is in sharp contrast with the HCM caused by mutations of the 
beta myosin heavy chain gene or the troponin T gene, in which the disease was almost 
fully penetrant by the age of 30. 
In our patient population we also found 5 mutation carrier family members above the age 
of 50, and 2 family members above the age of 60, in whom HCM had not been developed 
yet. The oldest age when HCM was diagnosed was 76 years. The clinical relevance of 
these observations is that in young adults it cannot be stated that a family member did not 
inherit the disease, as in MYBPC3 gene mutation carriers the disease manifests 
subsequently, maybe at an older age. In case of the above family members cardiology 
screening is recommended every 3-5 years or in case of complaints.  
 
5.3. Observation of extreme phenotypic variability in a HCM family carrying the 
MYBPC3 c.821+1G>A gene mutation  
The MYBPC3 c.821+1G>A mutation was first published by Niimura et al. (due to the 
different exon numbering in the form of Int8DSG+1A) in a two-generation family where 9 
mutation carriers were observed and 5 of them were clinically affected (58). There was no 
death in the family related to HCM. In the families analysed by Erdmann et al. that 
mutation was also described in two unrelated German families where 5 mutation carriers 
were found (49). The disease occurred at the age of 24-59, the left ventricular wall 
thickness was 19-24 mm, and there was 1 myomectomy, 1 ICD implantation and 2 septal 
alcohol ablations among the family members. By the analysis of the patients’ mRNA 2 
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aberrant transcriptions were detected in one case with the loss of the exon 7 and in the 
other case the exon 7/8, furthermore, with the activation of a hidden stop codon in the exon 
9. About the two apparently unrelated German families a common ‘founder’ haplotype was 
identified. That mutation was also noticed in the report from the Mayo Clinic (37). 
In the large Hungarian HCM family we investigated with the MYBPC3 c.821+1G>A gene 
mutation we observed an extremely variable phenotype, including symptom-free mutation 
carriers, sudden cardiac death, progression into dilated phase and complications of 
infective endocarditis. 
Early investigations looking at phenotype–genotype correlations in HCM observed a high 
degree of phenotypic variability which appeared to be partly explained by genetic 
heterogeneity (i.e. involvement of different disease genes). Some genes, or some particular 
mutations, were reported to be associated with a high risk for sudden cardiac death (e.g. 
TNNT2 mutations or MYH7 p.Arg403Gln mutation), modest LV hypertrophy (TNNT2 
mutations), or delayed cardiac expression (MYBPC3 mutations) (58,60,62-64). Subsequent 
studies, based primarily on individual patients rather than families, have reported 
exceptions and more heterogeneous cardiac expression within a given gene or mutation. 
With currently available methods for phenotyping, no clear and consistent correlations are 
detected for most of mutations. Our ability to draw more accurate genotype–phenotype 
correlations over the spectrum of disease will improve in the future as more robust and 
quantitative methods to assess phenotype are identified, and as we are able to follow larger 
genotyped cohorts over time. At a broader level, patients with complex genotype and 
multiple simultaneous mutations may have more severe or early disease expression, related 
to a gene dosage effect. This was clearly described in small families (51,65-67) and 
recently suggested in a larger study. Finally, some studies have observed that patients with 
a pathogenic sarcomere mutation had an increased risk of cardiovascular events, especially 
heart failure, compared with patients with negative genetic testing and no sarcomere 
mutation (34,68,69). 
 
5.4. Analysis of the MYBPC3 p.Gln1233Ter mutation in three carrier families  
The MYBPC3 p.Gln1233Ter mutation had a debated consequence in the literature. The 
importance of the mutation has been questioned based on the arguments that no affected-
to-affected transmission has ever been demonstrated and the mutation was found to be 
37 
 
present in apparently normal controls in some populations. In our study we were able to 
detect the p.Gln1233Ter mutation in three HCM families, and affected-to-affected 
transmission of the mutation was demonstrated in two of the three families. We also 
proved that the mutation was absent in a large cohort of control samples (928 
chromosomes in total). Based on the above findings we suggested that the p.Gln1233Ter 
mutation of the myosin binding protein C gene is a true causative mutation for 
hypertrophic cardiomyopathy, because affected-to-affected transmission of the mutation 
has been shown for the first time in two families, and it was not found in a large number of 
control samples. In addition, the characteristics of the mutation, being a stop codon 
mutation, also suggested a causative role. The former identification of the mutation in 
some control population in a previous report may have indicated more the presence of 
silent mutation carriers without signs and symptoms of the disease. The latter was also 
demonstrated in our families, as three of the 8 mutation carriers did not manifest the 
disease by the age of 18–37 years. 
Causation of a given genetic variant is impossible to prove with 100% certainty in most 
‘real life’ clinical cases. However, the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology have recently developed a 
guideline to give recommendations on this issue (70). This report recommends the use of 
specific standard terminology—“pathogenic,” “likely pathogenic,” “uncertain 
significance,” “likely benign,” and “benign”—to describe variants identified in genes that 
cause Mendelian disorders. Moreover, this recommendation describes a process for 
classifying variants into these five categories based on criteria using typical types of 
variant evidence (e.g. population data, computational data, functional data, and segregation 
data). On the basis of the above guideline, there are multiple lines of evidence to 
characterize the identified p.Gln1233Ter mutation we report as ‘pathogenic’. The variant 
possess the following characteristics: 1. Null (nonsense) variant (PVS1: very strong 
evidence of pathogenicity); 2. absent from controls (PM2: moderately strong evidence of 
pathogenicity); 3. protein length changes as a result of in-frame deletions/insertions in a 
no-repeat region or stop-loss variants (PM3: moderately strong evidence of pathogenicity); 
4. cosegregation with disease in multiple affected family members in a gene definitively 
known to cause the disease (PP1: supporting evidence of pathogenicity); 5. patient’s 
phenotype or family history is highly specific for a disease with a single genetic aetiology 
(PP4: supporting evidence of pathogenicity). 
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The MYBPC3 p.Gln1233Ter variant is currently listed with a comment of “with pathogenic 
allele” in the dbSNP database, and with comment of ‘pathogenic’ in the NCBI ClinVar 
database. According to the ExAC (ExAc Aggregated Populations) database, which 
provides data on the genotype of 60,706 unrelated individuals sequenced as part of various 
disease-specific and population genetic studies, the minor allele frequency of the 
p.Gln1233Ter variant is 0.000008%, pointing out that this variant is almost non-existent in 
the general population, which also strengthen the malignant nature of this variant. 
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6. SUMMARY AND CONCLUSIONS 
1. We identified known and novel MYBPC3 mutations in Hungarian patients with 
hypertrophic cardiomyopathy. 
Six causative myosin binding protein C gene mutations were identified in 45 Hungarian 
patients with HCM. Similarly to the existing literature knowledge, most of the mutations 
are predicted to cause shorter-than-normal, truncated proteins. The clinical appearance of 
the mutations was heterogeneous with high mortality rate in the index patients. 
 
2. We observed a prevalence of 13% of MYBPC3 gene mutations in the Hungarian 
HCM patient cohort, which makes the gene the most frequently affected gene in the 
Hungarian HCM population. 
The identification of 6 different causative MYBPC3 mutations out of 45 Hungarian patients 
with HCM establish a 13% prevalence rate of the MYBPC3 gene mutations in the 
Hungarian HCM patient population. Taking our previous data on disease gene distribution 
in Hungarian HCM population into consideration, the MYBPC3 gene seems to be the most 
commonly affected gene in the Hungarian patient population with HCM. 
 
3. We observed that HCM caused by MYBPC3 mutations may manifest at older ages 
in adulthood and its appearance is not typical at young age. Once the disease develops 
its clinical course is not benign but has a high mortality rate and may carry and 
increased risk for sudden cardiac death and progression into dilated phase.  
According to our data hypertrophic cardiomyopathy caused by the myosin binding protein 
C manifests especially at older ages, and its appearance is not typical at younger ages. 
Many patients were diagnosed with HCM above the age of 40, or even above the age of 50 
years. The course of HCM caused by MYBPC3 gene mutations which has already been 
manifested can be overtly malignant leading to sudden cardiac death or progression into 
the dilated phase. The latter observation also suggest that not the mutation carrier status 
itself, but the clinical manifestation and characteristics of HCM determine prognosis.  
 
4. An extremely variable phenotype of the MYBPC3 c.821+1G>A mutation was 
observed. 
In the large Hungarian HCM family we investigated with the MYBPC3 c.821+1G>A gene 
mutation we observed an extremely variable phenotype, including symptom-free mutation 
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carriers, sudden cardiac death, progression into dilated phase and complications of 
infective endocarditis. 
 
5. Observing that the MYBPC3 p.Gln1233Ter mutation was transmitted from 
affected-to-affected in two carrier families and that it was not present in a large 
number of controls we provided evidence that the variant is a causative mutation for 
HCM.  
In our work we were able to detect the MYBPC3 p.Gln1233Ter mutation in three carrier 
families, and affected-to-affected transmission of the mutation was demonstrated in two of 
the three families. We also proved that the mutation was absent in a large cohort of control 
samples (928 chromosomes in total). Based on the above findings we suggested that the 
p.Gln1233Ter mutation of the myosin binding protein C gene is a true causative mutation 
for hypertrophic cardiomyopathy. This observation is still holding true in the light of recent 
genetic data coming from large population studies. 
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9. APPENDIX 
